19.74
+0.03(+0.15%)
Currency In USD
Address
35 Gatehouse Drive
New York City, MA 02451
United States of America
Phone
781 419 1400
Website
Sector
Healthcare
Industry
Biotechnology
Employees
270
First IPO Date
March 02, 2016
| Name | Title | Pay | Year Born |
| Mr. Michael A. Metzger M.B.A. | Chief Executive Officer & Director | 1.24M | 1971 |
| Mr. Steven Closter | Chief Commercial Officer | 687,255 | 1969 |
| Mr. Luke J. Albrecht J.D. | Senior Vice President, General Counsel & Secretary | 703,548 | 1979 |
| Mr. Keith Alan Goldan CPA | Chief Financial Officer, Treasurer & Chief Accounting Officer | 736,241 | 1971 |
| Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder & Chief Scientific Officer | 0 | 1969 |
| Dr. Richard A. Heyman Ph.D. | Co-Founder | 0 | 1957 |
| Dr. Michael Downes Ph.D. | Co-Founder | 0 | N/A |
| Sharon Klahre | Vice President of Investor Relations & Communications | 0 | N/A |
| Dr. Ronald M. Evans Ph.D. | Co-Founder, Advisor and Chair of Scientific Advisory Board | 0 | 1950 |
| Mr. Kevin McManus | Chief People Officer | 0 | 1969 |
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.